Predicting Readmissions Using Omics, Biostatistical Evaluate and Artificial Intelligence
Recruiting · NCT05028686 · Observational (researchers observe without assigning treatment) · Lead sponsor: Institute for Clinical Evaluative Sciences
View the official record on ClinicalTrials.gov →Interventions studied
No intervention
What this trial is about
This study is a prospective registry that aims to predict readmissions in patients with heart failure, using -omics, machine learning, patient reported outcomes, clinical data and other high-dimensional data sources.
Who can take part
Age range
18 Years to 105 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Any patient aged 18 years or older admitted to hospital or seen in the emergency department with heart failure defined clinically
- The diagnosis will be guided by the Framingham criteria for HF and/or BNP. A BNP \>400 will be defined as definite heart failure and BNP 100-400 classified as possible heart failure.
- Provides informed consent
Exclusion criteria
- Patients who cannot communicate due to dementia or severe cognitive deficits
- non-Ontario residents
- nursing home residents
- those who are not discharged home but are discharged to a skilled nursing facility (long-term care or chronic institution)
- those who are unable to communicate who do not have a proxy (e.g. spouse or close family member) to facilitate communication with the patient.
Where it is running
1 location listed.
- University Health Network - Toronto, Ontario, Canada